Symbols

APLS

Apellis·NASDAQ

--(--)

APLS fundamentals

APLS Q4 2025 Earnings

Apellis (APLS) released its earnings on Feb 24, 2026: revenue was 190.34M (YoY -10.44%), missed estimates; EPS was 0.47 (YoY +262.07%), beat estimates.

Revenue / YoY

190.34M

-10.44%

EPS / YoY

0.47

+262.07%

Report date

Feb 24, 2026

APLS Earnings Call Summary for Q4,2025

Blockbuster Potential: EMPAVELI on track for 50% penetration in 5,000 U.S. patients, with Q4 2025 achieving 5% market penetration.
SYFOVRE Resilience: 17% YoY injection growth, 5-year data showing 1.5-year GA delay, and 2027 innovations (prefilled syringe, OCT-F).
Pipeline Breakthroughs: APL-9099 (base editing) IND expected H2 2026; FSGS/DGF trials expand kidney disease reach.
Financial Strength: $466M cash, $1B 2025 revenue, and disciplined spending to fund growth.

Earnings

EPS

Revenue

Revenue & Expenses

APLS has released its 2025 Q4 earnings report, with revenue of 199.91M, reflecting a YoY change of -5.94%, and net profit of -58.95M, showing a YoY change of -62.16%. The Sankey diagram below clearly presents APLS's revenue sources and cost distribution.

Key Indicators

Apellis (APLS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Apellis (APLS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Apellis (APLS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Apellis (APLS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown